180
Participants
Start Date
September 10, 2017
Primary Completion Date
March 1, 2020
Study Completion Date
March 10, 2022
BYL719
Patients will be instructed to take BYL719 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
Poziotinib
Patients will be instructed to take BYL719 orally at a dose of 12 mg once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
Nintedanib
Initial dose 200 mg twice per day orally according to study protocol.
Abemaciclib
Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
Durvalumab,Tremelimumab
Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
Seoul National University Hospital, Seoul
Korean Cancer Study Group
OTHER
Chungnam National University Hospital
OTHER
Seoul National University Hospital
OTHER